WO2003039555A3 - Agents for treating lesions of the nervous system - Google Patents

Agents for treating lesions of the nervous system Download PDF

Info

Publication number
WO2003039555A3
WO2003039555A3 PCT/DE2002/004140 DE0204140W WO03039555A3 WO 2003039555 A3 WO2003039555 A3 WO 2003039555A3 DE 0204140 W DE0204140 W DE 0204140W WO 03039555 A3 WO03039555 A3 WO 03039555A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
agents
lesions
treating lesions
neurons
Prior art date
Application number
PCT/DE2002/004140
Other languages
German (de)
French (fr)
Other versions
WO2003039555A2 (en
Inventor
Frank W Pfrieger
Daniela Mauch
Christian Goeritz
Karl Naegler
Original Assignee
Max Delbrueck Centrum
Frank W Pfrieger
Daniela Mauch
Christian Goeritz
Karl Naegler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Frank W Pfrieger, Daniela Mauch, Christian Goeritz, Karl Naegler filed Critical Max Delbrueck Centrum
Priority to EP02787354A priority Critical patent/EP1443941A2/en
Publication of WO2003039555A2 publication Critical patent/WO2003039555A2/en
Publication of WO2003039555A3 publication Critical patent/WO2003039555A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to agents and methods which influence the steroid content of neurons in order to increase the survival rate of neurons and to regenerate synapses after lesions of the nervous system. The invention also relates to the use of components of the nervous system that play a role in the steroid metabolism for diagnosing lesions.
PCT/DE2002/004140 2001-11-07 2002-11-07 Agents for treating lesions of the nervous system WO2003039555A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02787354A EP1443941A2 (en) 2001-11-07 2002-11-07 Agents for treating lesions of the nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10154221A DE10154221A1 (en) 2001-11-07 2001-11-07 Agent for the treatment of lesions of the nervous system
DE10154221.6 2001-11-07

Publications (2)

Publication Number Publication Date
WO2003039555A2 WO2003039555A2 (en) 2003-05-15
WO2003039555A3 true WO2003039555A3 (en) 2003-10-16

Family

ID=7704637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004140 WO2003039555A2 (en) 2001-11-07 2002-11-07 Agents for treating lesions of the nervous system

Country Status (3)

Country Link
EP (1) EP1443941A2 (en)
DE (1) DE10154221A1 (en)
WO (1) WO2003039555A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576073B2 (en) 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948421A (en) * 1982-09-13 1984-03-19 Yamanouchi Pharmaceut Co Ltd Antilipemic agent
EP0606012A1 (en) * 1993-01-06 1994-07-13 Scotia Holdings Plc Compositions containing cholesteryl esters of unsaturated fatty acids
WO1995013076A1 (en) * 1993-11-10 1995-05-18 Jenapharm Gmbh Use of steroids with a phenolic a-ring structure for prophylaxis and therapy of radical-mediated cell damage
WO1998025627A1 (en) * 1996-12-09 1998-06-18 American Home Products Corporation 17α-DIHYDROEQUILENIN FOR USE AS A MEDICAL ANTIOXIDANT
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002003985A1 (en) * 2000-07-07 2002-01-17 Saint Louis University Method of modulating expression of ldl-receptor-related protein and uses thereof
US20020077317A1 (en) * 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948421A (en) * 1982-09-13 1984-03-19 Yamanouchi Pharmaceut Co Ltd Antilipemic agent
EP0606012A1 (en) * 1993-01-06 1994-07-13 Scotia Holdings Plc Compositions containing cholesteryl esters of unsaturated fatty acids
WO1995013076A1 (en) * 1993-11-10 1995-05-18 Jenapharm Gmbh Use of steroids with a phenolic a-ring structure for prophylaxis and therapy of radical-mediated cell damage
WO1998025627A1 (en) * 1996-12-09 1998-06-18 American Home Products Corporation 17α-DIHYDROEQUILENIN FOR USE AS A MEDICAL ANTIOXIDANT
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002003985A1 (en) * 2000-07-07 2002-01-17 Saint Louis University Method of modulating expression of ldl-receptor-related protein and uses thereof
US20020077317A1 (en) * 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GORITZ CHRISTIAN ET AL: "Role of glia-derived cholesterol in synaptogenesis: New revelations in the synapse-glia affair.", JOURNAL OF PHYSIOLOGY PARIS, vol. 96, no. 3-4, pages 257 - 263, XP001146301, ISSN: 0928-4257 *
LAUDERBACK CHRISTOPHER M ET AL: "Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by Abeta(1-40): Implications for Alzheimer's disease.", BIOCHEMISTRY, vol. 40, no. 8, 27 February 2001 (2001-02-27), pages 2548 - 2554, XP002234730, ISSN: 0006-2960 *
MAUCH D H ET AL: "Glia-derived cholesterol promotes CNS synaptogenesis.", BIOLOGY OF THE CELL (PARIS), vol. 93, no. 3-4, October 2001 (2001-10-01), First Joint French-German Congress on Cell Biology;Strasbourg, France; November 07-09, 2001, pages 195, XP002234729, ISSN: 0248-4900 *
MAUCH DANIELA H ET AL: "CNS synaptogenesis promoted by glia-derived cholesterol.", SCIENCE (WASHINGTON D C), vol. 294, no. 5545, 2001, pages 1354 - 1357, XP002234731, ISSN: 0036-8075 *
PATENT ABSTRACTS OF JAPAN vol. 008, no. 138 (C - 231) 27 June 1984 (1984-06-27) *

Also Published As

Publication number Publication date
WO2003039555A2 (en) 2003-05-15
EP1443941A2 (en) 2004-08-11
DE10154221A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2003099207A3 (en) Oral lactoferrin in the treatment of respiratory disorders
WO2005039597A3 (en) Immunemodulating oligosaccharides
WO2007065918A3 (en) Method for purifying fsh or a fsh mutant
CA2205134A1 (en) A method for treating vascular headaches
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
AU2001249579A1 (en) Surface treatment method for magnesium alloys and magnesium alloy members thus treated
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
IL164828A0 (en) Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2003039555A3 (en) Agents for treating lesions of the nervous system
WO2001022958A3 (en) A pharmaceutical composition containing lycopene for stabilising atherosclerotic plaques
AU2001232390A1 (en) The method of the game for one to many persons on the online
WO2002066068A3 (en) Method of treating neurological diseases
WO2004016151A3 (en) Pthrp-derived modulators of smooth muscle proliferation
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2002016430A3 (en) Peptide with effects on cerebral health
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2004071419A3 (en) Methods and compositions for modulating glutamate transport activity in the nervous system
WO2002012901A3 (en) Use of grf1 protein for screening molecules
WO2003063784A3 (en) MOLECULES THAT MODULATE GαQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE
WO2006066110A3 (en) Cav2 RELATED COMPOSITIONS AND METHODS
WO2000051585A3 (en) Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
WO2001087305A3 (en) Method for treating functional dyspepsia using alosetron
TW200728316A (en) Method for purifying FSH or a FSH mutant
WO2004058154A3 (en) Method of identifying therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002787354

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002787354

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002787354

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP